FDA approves high-dose Fluzone for older patients

12/23/2009 | Reuters

Sanofi Pasteur secured FDA approval to promote a high-dose formulation of its Fluzone seasonal flu vaccine for people 65 and older. Sanofi's application was supported by clinical data showing the superiority of high-dose Fluzone over its original formulation in eliciting an immune response.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI